Gastrointestinal Therapeutics market Growth and Forecast Report 2025Posted by rekha on September 12th, 2019 Precision Business Insights (PBI) in its report titled “Global Gastrointestinal Therapeutics market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2024” assesses the market performance over seven years forecast period over 2018-2024. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. The global gastrointestinal therapeutics market was valued at US$ XX Mn in 2018 and increasing at a significant CAGR over the forecast timeframe owing to surge in the incidence of bacterial diseases such as tuberculosis, increasing number of manufacturing companies, factors such as resistance developed by the bacteria for blockbuster drugs, presence of characteristics such as bactericidal, concentration-dependent killing action, and activity against staphylococci, certain mycobacteria in humans and against E. coli, Proteus, Pseudomonas, Salmonella, Shigella, Serratia, and Enterobacter in animals are expected to drive the global gastrointestinal therapeutics market. However,adverse effects associated with the use of gastrointestinal therapeutics such as irreversible hearing loss, muscle twitching, and seizure are anticipated to hinder the revenue share of global gastrointestinal therapeutics market. Global gastrointestinal therapeutics market segmented on the basis of drug, product, mode of administration, application, distribution channel, and Geography. For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=37257 Intravenous Route Dominates the Global Gastrointestinal Therapeutics market Based on route of administration, global gastrointestinal therapeutics market segmented into oral, intravenous and others. Among them intravenous route dominated the global gastrointestinal therapeutics market in 2018 in term of revenue and estimated to dominate over the forecast period, owing to its quick on set of action, high bioavailability, and the high price of intravenous products compared to oral products. However, the oral route products dominated the global gastrointestinal therapeutics market in terms of volume in 2018 and estimated to dominate over the forecast period, owing to the patient compliance, ease of administration. Moreover, the limitations of the intravenous products like pain at the site of injection, high cost surge the market over the forecast years. North America Leads the Global Gastrointestinal Therapeutics market PBI’s global gastrointestinal therapeutics market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis, North America accounted for larger revenue share through 2014-2018 and expected to dominate over 2019-2025 owing to the High prevalence rate of ulcers, high incidence of chronic gastrointestinal diseases, presence of major suppliers of gastrointestinal therapeutics in the region, advanced healthcare system and product approvals are anticipated to propel the market. Asia Pacific gastrointestinal therapeutics market projected to exhibit significant growth due to increase in research and development, increasing patient pool due to change in life style, presence of major generic players in the region, and increase in healthcare expenditure boost the market.
Launch of newer formulation products, frequent product approvals, and strategic alliances are the key strategies adopted by market players Global gastrointestinal therapeutics market further reveals that the key players increasingly adopting strategies such as launch of newer technologies of needle free injector products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For instance, in 2018, HiFiBiO Therapeutics collaborated with Takeda pharmaceutical company for the discovery of breakthrough antibody therapies to potentially treat a variety of gastrointestinal diseases, cancers and other disorders. Key player’s profiles in the report are
Detailed Segmentation
By Drug Class
By Product Type
By Route of administration
By Application
By Distribution channel
Geography
For more information: https://www.precisionbusinessinsights.com/market-reports/gastrointestinal-therapeutics-market/ Like it? Share it! More by this author |